Loading...
These researchers conducted a pilot, manufacturer-supported, multisite, double-blind, placebo-controlled 8-week trial to ascertain whether extended-release guanfacine would be effective for chronic tics of moderate or greater global severity and thus warrant a larger trial.
The 34 child participants had a mean age of 11 years (range, 6–17; 68% boys). Stable medication was allowed. Guanfacine and placebo groups did not significantly differ on comorbidity with attention-deficit/hyperactivity disorder (ADHD; 50% vs. 22%) or obsessive-compulsive disorder (19% vs. 17%). Mean XR-guanfacine dose was 2.6 mg.
No significant differences between XR-guanfacine and placebo occurred on the primary measure of tic severity or on a global measure of improveme…